Juvenile pilocytic astrocytomas (JPA) account for 60--80% of paediatric low-grade astrocytomas (LGA), the most common paediatric brain tumour, and thus are the most frequently encountered subtype of brain neoplasm in children under the age of 19 years. They are classified according to the World Health Organisation (WHO) as WHO grade I ([Louis *et al*, 2007](#bib23){ref-type="other"}), and occur sporadically throughout childhood or arise in up to 15--40% of children affected with neurofibromatosis type 1 (NF1; [Pollack and Mulvihill, 1997](#bib27){ref-type="other"}). JPA exhibit distinct features, readily distinguishable from their other LGA counterparts, including clinical course and molecular characteristics, and have better prognosis in affected children ([Gajjar *et al*, 1997](#bib11){ref-type="other"}; [Ishii *et al*, 1998](#bib16){ref-type="other"}; [Cheng *et al*, 2000](#bib4){ref-type="other"}; [Tada *et al*, 2003](#bib37){ref-type="other"}; [Broniscer *et al*, 2007](#bib2){ref-type="other"}; [Fisher *et al*, 2008](#bib9){ref-type="other"}).

Even though they share similar histology, there is heterogeneity between sporadic JPA in terms of localisation, radiologic features, histologic atypia and clinical behaviour, all of which argue for the possibility of genetic disparity between potential JPA subgroups. Typically, JPA occur as exophytic cerebellar tumours, however, they can also arise in the brain stem or the optic pathway, where they behave more aggressively than NF1-associated JPA ([Grill *et al*, 2000](#bib13){ref-type="other"}), or, more rarely, in the cerebral hemispheres. Maximal surgical resection is the mainstay of therapy, and failure to achieve it remains the main therapeutic concern. Although cerebellar JPA are readily amenable to complete surgical resection, in other less anatomically accessible locations, surgery may result in the persistence of residual disease, which can require further therapy for tumour control, and ultimately lead to increased morbidity/mortality. In addition, some of these extracerebellar JPA seem less circumscribed and may exhibit atypical pathologic features, leading to pathologic misdiagnosis, including into higher grade tumours.

Until recently, the few genetic abnormalities documented in JPA mainly identified chromosomal gains of 7q and trisomy of chromosomes 5, 7 or 8 in some tumours ([White *et al*, 1995](#bib42){ref-type="other"}; [Rickert and Paulus, 2004](#bib32){ref-type="other"}; [Wemmert *et al*, 2006](#bib41){ref-type="other"}). Recently several consecutive papers described duplication of 7q34 in LGA including JPA ([Bar *et al*, 2008](#bib1){ref-type="other"}; [Deshmukh *et al*, 2008](#bib7){ref-type="other"}; [Jones *et al*, 2008](#bib19){ref-type="other"}; [Pfister *et al*, 2008](#bib25){ref-type="other"}; [Sievert *et al*, 2008](#bib35){ref-type="other"}). However, the data reported are conflicting regarding the subgroup of LGA affected by this genetic event, the size of the duplication and its anatomical localisation within the brain. Indeed, [Deshmukh *et al* (2008)](#bib7){ref-type="other"} identified amplification of 7q34 in 8 of 10 cerebellar JPA at 138151200--139456000, which included *HIPK2*, a potential gene of interest. The authors further showed using an immunohistochemical approach that overexpression of HIPK2 was more frequent in LGA than in high-grade gliomas, and that it was more common in infratentorial tumours. Their silencing of *HIPK2* in U87 (a glioblastoma (GBM) cell line) decreased the cells proliferation rate. [Pfister *et al* (2008)](#bib25){ref-type="other"} identified duplication of 7q34 within 139186224--140156951 in 30 of 66 (45.5%) paediatric LGA. This region included *BRAF*, a gene which was not in the genetic interval described in [Deshmukh *et al* (2008)](#bib7){ref-type="other"}. The authors confirmed the absence of previously described *BRAF* oncogenic mutations in their sample set, and showed that silencing of *BRAF* in a LGA cell line decreased cell proliferation rates. However, based on lower resolution BAC arrays, they did not precisely map the genetic region missing other genes potentially critical in the pathogenesis of LGA, including *HIPK2*. In addition, data from this report suggest that LGA other than JPA may harbour 7q34 duplication and that this genetic alteration is more frequent in non-cerebellar tumours.

Recent reports have indicated a central role for the mitogen-activated protein kinase (MAPK) pathway in the tumorigenesis of pilocytic astrocytomas and showed that duplication at 7q34 leads to a fusion between *KIAA1549* and *BRAF* resulting in constitutive activation of the BRAF kinase ([Jones *et al*, 2008](#bib19){ref-type="other"}; [Sievert *et al*, 2008](#bib35){ref-type="other"}). In particular, [Jones *et al* (2008)](#bib19){ref-type="other"} focused on JPA and describe a tandem duplication at 7q34 producing a transforming BRAF fusion gene in 29 of 44 tumours (66%), and V600E point mutation of BRAF in two further cases. Sievert *et al* indicated that 7q34 duplication occurs in 17 of 22 JPA but also report it in 3 of 6 diffuse astrocytomas (LGA grade II).

To determine the specificity of 7q34 duplication to a given subgroup of LGA and identify additional genetic aberrations in tumours that do not carry this duplication, we investigated 115 paediatric brain tumour samples including 57 JPA, and 27 diffuse astrocytomas ([Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}). Our data indicate that 7q34 duplication is exclusive to JPA and a hallmark of specific anatomical localisations of these tumours within the brain. We identify additional genetic abnormalities in JPA that do not harbour 7q34 duplication, which may help shed light on their pathogenesis. Data from gain of function analysis in immortalised astrocytes further confirm that increased expression of wild-type *BRAF* is unable to cause malignant transformation on its own however may contribute to an increased response to exogenous triggering of membrane receptors. Moreover, we show that the MAPK pathway is active in all JPA regardless of 7q34 duplication and that all of these tumours may be amenable to therapeutic targeting of this pathway.

Materials and methods
=====================

Samples
-------

All samples were obtained with informed consent after approval of the Institutional Review Board of the respective hospitals they were treated in, and independently reviewed by senior paediatric neuropathologists (SA, CH, ZH) according to the WHO guidelines ([Kleihues *et al*, 2002](#bib22){ref-type="other"}). A total of 115 paediatric brain tumours (average 9.4±4.7 years) were analysed ([Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}); 57 JPA (53 sporadic, 4 from NF1 Patients), 27 diffuse astrocytomas (grade II), 1 grade II ependymoma, 5 grade I gangliogliomas and 25 high-grade astrocytomas (HGA) were included. There were no pylomixoid variants within the JPA included within this study. All samples were taken at the time of the first surgery before further treatment, when needed. Tissues were obtained from the London/Ontario Tumor Bank, and from collaborators in Montreal, Toronto and Hungary.

DNA extraction and hybridisation, SNP analysis
----------------------------------------------

DNA from frozen tumours was extracted as described previously ([Wong *et al*, 2006](#bib43){ref-type="other"}). For SNP analysis, DNA (250 ng) from 40 samples was assayed with the Human Hap300-Duo (*N*=28) and the 610-Qad (*N*=16) genotyping beadchips according to the recommendations of the manufacturer (Illumina, San Diego, CA, USA). These BeadChips enable whole-genome genotyping of respectively over 300 000 and 610 000 tagSNP markers derived from the International HapMap Project ([www.hapmap.org](http://www.hapmap.org)) with a mean intermaker distance of 10 and 5 kb respectively. Image intensities were extracted using Illumina\'s BeadScan software. Data for each BeadChip were self-normalised using information contained within the array. Penn-CNV ([Wang *et al*, 2007](#bib40){ref-type="other"}) and GqCNV (D Serre *et al*, unpublished) algorithms were applied on the genotype data derived from the 40 LGA. Only the alterations that were detected by both algorithm and that contained more than 5 consecutive SNPs were considered in this study. They were further confirmed by visualisation in the BeadStudio.

Validation of copy number changes by quantitative real-time PCR
---------------------------------------------------------------

Quantitative real-time PCR (q-PCR) was done on an ABI-Prism 7000 sequence detector (Applied Biosystems, Bedford, MA, USA) using a SYBR Green kit (Applied Biosystems). The target locus from each tumour DNA was normalised to the reference, Line-1 as previously described ([Wong *et al*, 2006](#bib43){ref-type="other"}; [Supplementary Table 1](#sup1){ref-type="other"}).

Cell lines, antibodies and transfections
----------------------------------------

hTERT-immortalised human astrocytes (kind gift of Dr A Guha, Labbatt Brain Tumour Research Centre, Ontario, Canada) were grown and transfected with 2 *μ*g of plasmid DNA encoding wild-type C-Myc-Braf using Fugene 6 (Roche, Mississauga, ON, Canada) as previously described ([Shi *et al*, 2004](#bib34){ref-type="other"}). Unless stated otherwise, all antibodies used were obtained from Cell Signaling (Danvers, MA, USA). Transfected cells were used at 0, 48 and 72 h posttransfection. HIPK2 plasmids were generously provided by Dr Gabriella D\'Orazi (Regina Elena Cancer Institute, Rome, Italy), and BRAF plasmids by Dr Richard Marais (Cancer Research, London, UK).

Western blot and immunofluorescence analysis
--------------------------------------------

Extracts were prepared from cell pellets and western blot analysis performed on total lysates as previously described ([Jabado *et al*, 1998](#bib17){ref-type="other"}; [Rajasekhar *et al*, 2003](#bib31){ref-type="other"}). Cross-reactivity was visualised by ECL chemiluminescence (Amersham) on a phosphorimager. For immunofluorescence analysis images were acquired using a Retiga 1300 digital camera (QIMAGING) and a Zeiss confocal microscope.

Immunohistochemical analysis
----------------------------

Immunohistochemical analyses for phospho-Erk (pErk), were performed and the slides scored as previously described ([Faury *et al*, 2007](#bib8){ref-type="other"}).

\[3H\]Thymidine incorporation assay
-----------------------------------

DMEM (10 ml) containing 7.4 kBq (0.2 mCi) of \[methyl-3H\]thymidine (Amersham Pharmacia Biotech Europe, Freiburg, Germany; Batch 215, 65 Ci mM) were added to each microplate well. Experiments were done in triplicate at least three times with identical results.

Results
=======

Copy number variants in 40 LGA
------------------------------

To chart genomic alterations in our sample set, we first performed a high-resolution genome-wide screen of the samples using the SNP arrays. The copy number variant (CNV) analysis of the resulting dataset generated on the Human Hap300-Duo and 610-Qad arrays gave similar results for both platforms. All samples had at least one CNV and the overall frequency of CNVs according to the chromosomal position showed that most tumours had only focal abnormalities, some of them previously reported. Most LGA did not have chromosome-wide gains or deletions, with the exception of two JPA samples, which had gains of the whole chromosome 7 ([Supplementary Table 2](#sup1){ref-type="other"}). Regions with loss-of-heterozygosity were rarely found in LGA. We found a single region showing recurrent gain of 7q34 in 20 of 40 (50%) samples (minimal common region of gain for all tumours on chromosome 7:138380901--140119915, NCBI Build 36.3; [Figure 1](#fig1){ref-type="fig"}). The gain specifically corresponds to a chromosomal duplication, according to the Illumina Plots. A total copy number of 3 was inferred based of the logR ratio plot that is characterised by an upward deflection from 0 to 0.35 and by a split in the heterozygous allele frequencies (B-allele frequency measure) into two populations, one located at 0.67 (2 : 1 ratio) and the other at 0.33 (1 : 2 ratio; [Figure 1](#fig1){ref-type="fig"}). This gain in 7q34 is a somatic event as it was present in the tumour and not in DNA from peripheral blood taken from the same patients (*n*=7), thus excluding a germ-line segmental duplication (data not shown). It was not found in a set of 1363 control DNA analysed with the Illumina Human-Hap 300K platform ([Hakonarson *et al*, 2007](#bib14){ref-type="other"}) or in the 25 HGA included in this study.

7q34 duplication involves both BRAF and HIPK2 genes and is more frequent in extrahemispheric JPA
------------------------------------------------------------------------------------------------

To validate amplification of the genetic interval we identified, DNA was extracted from 17 samples analysed by SNP arrays and an additional independent set of 55 samples including 22 JPA ([Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}). We performed quantitative real-time PCR (qPCR) on genes included within (*HIPK2* -- *homeodomain-interacting protein kinase 2*; *TBXAS1 -- thromboxane synthetase 1*), at the edge (*BRAF*) and located just after (*MRPS33*) the interval of interest ([Figure 1](#fig1){ref-type="fig"}). The resulting profiles further confirm those obtained by SNP arrays and show that 26 of 72 samples have a detectable amplification of *HIPK2*, *TBXAS1* and *BRAF*, and that most samples have normal copy number of *MRPS33*, which was located just outside of the genetic interval of interest on chromosome 7q34 ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}; [Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}). Levels of messenger RNA for *BRAF* and *HIPK2* were also tested using quantitative RT-PCR, as previously described ([Faury *et al*, 2007](#bib8){ref-type="other"}; [Haque *et al*, 2007](#bib15){ref-type="other"}), in seven samples with 7q34 duplication, and were in the range of 1.7--5 (data not shown).

Based on concordant results we considered the amplification of *HIPK2*, *TBXAS1* and *BRAF* by qPCR analysis to reflect duplication of the 7q34 region. We thus combined SNP and qPCR data, and further determined the incidence of 7q34 duplication based on histology, for example, sporadic JPA (*N*=53), NF1-associated JPA (*N*=4), diffuse astrocytomas (*N*=27) and the other paediatric brain tumours (*N*=31). 7q34 duplication was only present in sporadic JPA. Indeed, it was identified in 35 of 53 (66%) JPA, and was absent in NF1-associated JPA and the other brain tumours ([Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}). Remarkably, this duplication was more prevalent in tumours originating from specific sites within the brain. In this regard, we found this amplification in 24 of 30 (80%) of cerebellar and 10 of 16 (62.5%) of brainstem/hypothalamic/optic-pathway JPA, whereas only 1 of 7 of hemispheric JPA had this duplication, which did not include BRAF ([Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}; *P*\<0.001). We also sequenced *BRAF* in 52 samples and found point mutations affecting the hot spot codon 600 in exon 15 of *BRAF*, V600E (an activating mutation previously described in melanomas and other cancers ([Wan *et al*, 2004](#bib39){ref-type="other"})) only in 1 JPA and 1 grade II ganglioglioma ([Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}; [Supplementary Table 3](#sup1){ref-type="other"}) in keeping with previous studies ([Jeuken *et al*, 2007](#bib18){ref-type="other"}; [Jones *et al*, 2008](#bib19){ref-type="other"}; [Pfister *et al*, 2008](#bib25){ref-type="other"}).

Copy number variants in JPA without 7q34 duplication
----------------------------------------------------

We investigated genetic aberrations occurring specifically in JPA not carrying 7q34 duplication analysed by SNP arrays (*N*=10) and identified recurrent abnormalities ([Table 3](#tbl3){ref-type="table"}). Amplification of 19p13 including killer receptor inhibitory genes (KIR) genes regulating the activity of natural killer cells within the immune system was identified in 5 of 10 JPA. A recurrent region of amplification at 12p11.21 was also identified in 7 of 10 JPA and 2 of 5 grade II LGA. It includes genes with unknown function and *OVOS2*, a gene similar to ovostatin, a proteinase inhibitor involved in innate immune responses. These data suggest that genes involved in immune modulation may be important in the pathogenesis of another subgroup of JPA, which does not harbour 7q34 duplication.

The MAPK pathway is activated in all JPA regardless of 7q34 duplication
-----------------------------------------------------------------------

To assess whether BRAF amplification in the absence of mutation can be correlated with increased activity of the RAF/MEK/ERK pathway, we used immunohistochemical analysis based on antibodies against the phosphorylated (activated) form of ERK1--2 (pERK). Sections from samples for which we had fixed paraffin embedded slides were tested for pERK ([Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}) immunoreactivity and scored as previously described (Faury *et al*, 2007). Results show that the astrocytic component of all JPA stained positively for pERK. This result indicates that the MAPK pathway is triggered in LGA, including JPA, regardless of *BRAF* copy number status or activating mutation.

Functional characterisation of BRAF and/or HIPK2 overexpression in immortalised mature astrocytes
-------------------------------------------------------------------------------------------------

To assess the potential of increased levels of wild-type BRAF to drive increased activity of mitogenic pathways in cells of glial origin we used hTERT-immortalised astrocytes ([Kamnasaran *et al*, 2007](#bib21){ref-type="other"}) as recipients of transient overexpression of genes from the 7q34 region, wild-type (WT) *BRAF*, *HIPK2* or both. Mutant *V600E BRAF* was used as a positive control for transformation of astrocytes. Transfection efficiency was estimated by immunofluorescence analysis against the C-Myc and FLAG tags to be approximately ∼40--50% at 48, 72 and 96 h ([Figure 4A and B](#fig4){ref-type="fig"}). No foci of transformation or morphological changes were observed in cells transfected with WT constructs, whereas transformation foci were readily distinguishable in V600E transfectant cells. Proliferation assays revealed no change in growth of cells overexpressing of *BRAF, HIPK2* or both, compared to their mock-transfected controls ([Figure 4C](#fig4){ref-type="fig"}). Similarly, overexpression of BRAF had no discernible effect on the baseline level of ERK expression or phosphorylation ([Figure 4D](#fig4){ref-type="fig"}). Indeed, in serum starved EV and C-Myc-BRAF transfectant cells pERK was similar in intensity in both settings, in keeping with previous findings in COS cells ([Ciampi *et al*, 2005](#bib5){ref-type="other"}). Remarkably, exposure of BRAF overexpressing cells to ligands of the epidermal growth factor receptor (EGFR), such as transforming growth factor-*α* or EGF increased pERK levels by a mean of ∼5.9-fold relative to 2.3-fold in empty-vector transfectants (mean of three distinct experiments, [Figure 4D](#fig4){ref-type="fig"}). These results indicate that although BRAF overexpression may not be sufficient to drive proliferative responses of astrocytic cells it may sensitise them to exogenous growth factors.

Discussion
==========

We show that somatic duplication of 7q34 in LGA is specific to JPA. We also establish that its prevalence varies with the site of origin within the brain of the JPA, and is more frequent in cerebellar (24 of 30 -- 80%) followed by brainstem and optic pathway tumours (10 of 16 -- 62.5%), whereas it is rare in hemispheric JPA (1 of 7 -- 14%; [Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}; [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Our analysis and the several validation steps we performed characterise this region with increased precision compared to the recently published concurrent studies, which missed either BRAF or HIPK2 ([Deshmukh *et al*, 2008](#bib7){ref-type="other"}; [Jones *et al*, 2008](#bib19){ref-type="other"}; [Pfister *et al*, 2008](#bib25){ref-type="other"}) and confirm that 7q34 amplification includes both *BRAF* and *HIPK2* in as many as 34 of 35 JPA samples. We identify additional genetic regions in JPA without 7q34 duplication ([Table 3](#tbl3){ref-type="table"}) and show that most genes within these regions are modulators of the immune system.

Specificity of 7q34 duplication to JPA and its prevalence in infratentorial tumours contrast with previous reports alluding that 7q34 duplication may be present in non-JPA LGA ([Deshmukh *et al*, 2008](#bib7){ref-type="other"}; [Pfister *et al*, 2008](#bib25){ref-type="other"}; [Sievert *et al*, 2008](#bib35){ref-type="other"}) and is more frequent in non-cerebellar LGA ([Pfister *et al*, 2008](#bib25){ref-type="other"}; [Sievert *et al*, 2008](#bib35){ref-type="other"}). Deshmukh *et al* showed 7q34 duplication in 8 of 10 cerebellar JPA and further used increased HIPK2 expression on tissue microarray as a surrogate for marker for this genetic event. Other molecular events, distinct from 7q34 duplication, may lead to *HIPK2* overexpression ([Sombroek and Hofmann, 2009](#bib36){ref-type="other"}) and may account for increased HIPK2 levels in tumours other than JPA. We chose to validate the genetic interval we identified through concordant increased copy number by qPCR of three consecutive genes within it (*HIPK2*, *TBXAS1*, *BRAF*) in a large number of samples, and thus show specificity of 7q34 duplication to JPA. The lower resolution BAC-arrays used by Pfister *et al* led them to underestimate the size of the duplication (0.94 Mb instead of the ∼1.74 Mb, we and others describe) and might have led the authors to miss this duplication in a number of cerebellar JPA samples. Indeed, when we revisited data collectively published by the other groups we found that JPA within the cerebellum have the highest incidence for this duplication. In addition, in [Jones *et al* (2008)](#bib19){ref-type="other"}, which focused on JPA, the authors indicate 7q34 duplication might be more prevalent in infratentorial tumours, also in keeping with our data. They also show that one sample was classified as a grade II astocytoma; however, the child had prolonged disease-free survival more in keeping with a diagnosis of JPA. This misclassification might also account for the findings of 7q34 duplication in some non-JPA LGA in the study by the other groups ([Deshmukh *et al*, 2008](#bib7){ref-type="other"}; [Pfister *et al*, 2008](#bib25){ref-type="other"}; [Sievert *et al*, 2008](#bib35){ref-type="other"}). The central review of samples by senior paediatric neuropathologists we performed has been shown to increase reproducibility of neuropathologic classification of tumours ([Pollack *et al*, 2003](#bib26){ref-type="other"}) and may account for increased accuracy in our dataset. Our findings and these from recent studies alluding to the presence of different molecular signatures in sporadic JPA based on its region of origin ([Sharma *et al*, 2007](#bib33){ref-type="other"}) make it tempting to speculate that, like CNS ependymoma ([Taylor *et al*, 2005](#bib38){ref-type="other"}), variants of JPA might arise from a unique site-restricted progenitor cell.

RAF kinases are components of a conserved signalling pathway that regulates cellular responses to extracellular signals ([Wan *et al*, 2004](#bib39){ref-type="other"}). Their role in glioma formation, and the role of the MAPK cascade they trigger, have been identified in tumour samples and further confirmed in mouse models ([Jeuken *et al*, 2007](#bib18){ref-type="other"}; [Pritchard *et al*, 2007](#bib29){ref-type="other"}; [Lyustikman *et al*, 2008](#bib24){ref-type="other"}; [Pfister *et al*, 2008](#bib25){ref-type="other"}). *NF1* encodes for a Ras-GTPAse and its loss of function may lead to activation of Ras/RAF signalling and coincides with formation of indolent JPA mainly within the optic pathway. Our exploration of immortalised astrocytes show that overexpression of wild-type *BRAF* may not be sufficient by itself to mediate the activation of the MAPK cascade. In keeping with these data, only oncogenic *BRAF* mutations have been implicated in tumours of epithelial ([Rajagopalan *et al*, 2002](#bib30){ref-type="other"}) and neuroectodermal origin ([Brose *et al*, 2002](#bib3){ref-type="other"}; [Pollock *et al*, 2003](#bib28){ref-type="other"}). 7q34 duplication in JPA was recently shown to produce novel oncogenic BRAF fusion genes with transforming capacity ([Jones *et al*, 2008](#bib19){ref-type="other"}), similar to findings in radiation-associated papillary thyroid cancer ([Ciampi *et al*, 2005](#bib5){ref-type="other"}) where an intrachromosomal inversion, and not duplication, let to this oncogenic event. These data indicate that wild-type *BRAF* would be unlikely to induce transformation. Tumours in which the duplication occurs without this in-frame fusion or in patients with trisomy of the full chromosome 7 require other mechanisms to activate BRAF and induce oncogenesis. Intriguingly, our data suggest that all JPA have active MAPK pathway regardless of 7q34 duplication ([Figure 3](#fig3){ref-type="fig"}). In keeping with the importance of the MAPK pathway in JPA genesis, two additional alternative mechanisms resulting in MAPK activation were very recently identified in JPA ([Jones *et al*, 2009](#bib20){ref-type="other"}). This group studied the 10 JPA for which V600E point mutation of BRAF (2 of 44), clinical diagnosis of NF1 (3 of 44) or the common BRAF fusion following 7q34 duplication (29 of 44) could not be found ([Jones *et al*, 2008](#bib19){ref-type="other"}). In one patient they found tandem duplication at 3p25 producing an in-frame oncogenic fusion between SRGAP3 and RAF1, a finding corroborated by a concurrent group on additional patients with JPA and no clinical NF1, 7q34 duplication or BRAF mutations ([Forshew *et al*, 2009](#bib10){ref-type="other"}). This genetic event bears striking resemblance to the common *KIAA1549 BRAF* fusion event and the fusion protein includes the Raf1 kinase domain, and shows elevated kinase activity when compared with wild-type Raf1. Secondly, in one patient with JPA a novel 3 bp insertion at codon 598 in BRAF mimics the hotspot V600E mutation to produce a transforming, constitutively active BRaf kinase ([Jones *et al*, 2009](#bib20){ref-type="other"}). These findings further imply that BRAF or RAF1 constitutive activation, achieved through different genetic events, converge to activate the MAPK pathway and that this pathway could be clinically targeted in all JPA.

Gains in 7q34 have been described in other cancers including ovarian cancer. However these are amplifications and not duplications and the region involved has some but no complete overlap with the one identified in JPA. Also, genetic analysis of medulloblastomas ([Gilbertson and Ellison, 2008](#bib12){ref-type="other"}), ependymomas ([Taylor *et al*, 2005](#bib38){ref-type="other"}) and high-grade astrocytomas (our data) do not identify 7q34 duplication in these tumours making this genetic event specific to JPA. Unscheduled activation of the MAPK pathway may lead to cellular senescence, which could function to limit tumour development ([Courtois-Cox *et al*, 2006](#bib6){ref-type="other"}). Therefore we also postulate that oncogenic BRAF may cooperate with other, presently unknown changes, to drive formation of a subset of JPA at the same time it may drive activation of other pathways including cellular senescence. Ultimately, this may make this tumour less aggressive, similar to what is observed in melanocytes where oncogenic *BRAF* mutations result only in naevi formation. As complete surgical removal is the rule for cerebellar JPA, studies compiling higher numbers of JPA, occurring in other locations, are needed to establish whether 7q34 duplication is indeed associated with improved progression-free survival, as well as the biological mechanisms controlling these variables.

In summary, our studies suggest that the 7q34 region may play a site-specific role in pathogenesis of JPA and that the involvement of an active MAP kinase signalling pathway through oncogenic BRAF and other RAF family members in this process is crucial. They further emphasise the relevance of therapeutic targeting of this pathway in all JPA. To avoid misdiagnosis and adapt therapies, all infratentorial LGA should be screened by immunohistochemistry for active MAP kinase pathway (phosphorylated ERK) and further tested for the presence of 7q34 duplication, then, in its absence, 3p25 gain or BRAF mutation. Further functional evaluation of genes included within this genetic interval, others we identify herein, and others involved in the MAP kinase cascade and their correlation in larger sample sets to the site of origin, age of the patient and progression-free survival will help shed light on the pathogenesis of JPA.
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Duplication of 7q34 visualised using BeadStudio. (**A**) Chromosome-wide data showing duplication at 7q34 through the increase in the log R ratio values (top) and split in the B allele frequencies (bottom) plotted for each SNP for one JPA sample (Patient 10; [Table 1](#tbl1){ref-type="table"}). (**B**) Zoom-in showing genes included within the region of interest. (**C**) Detailed view of the 7q34 locus amplified in each of the 20 JPA samples. Genes within and outside the region of interest are shown on the left. Genes we further used to validate duplication within this dataset and an additional dataset of 35 tumours are bolded.
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![*HIPK2*, *TBXAS1*, *BRAF* and *MRPS33* copy number in the brain tumours included in this study. DNA qPCR-based copy number for *HIPK2*, *TBXAS1*, *BRAF* and *MRPS33* are plotted. The cut-off for DNA copy number was set using the mean of ±2 s.d. (plotted lines) against *MRPS33*, which was located after the genetic interval of interest ([Figure 1](#fig1){ref-type="fig"}).](6605179f2){#fig2}

![The astrocytic component of all the brain tumours included in this study show MAPK pathway activation regardless of BRAF copy number. Immunohistochemical analyses for phosphorylated ERK (pERK), used as a surrogate marker of MAPK pathway activation were performed for the 52 samples included in this study for which formalin-fixed paraffin-embedded slides were available. Sections were stained using anti-pERK followed by detection using the DAKO kit (red accounts for positive staining) and hematoxylin counterstaining. Staining intensity was scored as in ([Faury *et al*, 2007](#bib8){ref-type="other"}; [Haque *et al*, 2007](#bib15){ref-type="other"}). Full characteristics of samples are provided in [Tables 1](#tbl1){ref-type="table"}, [2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}.](6605179f3){#fig3}

![Functional analysis of *BRAF* and *HIPK2* overexpression in hTERT-immortalised astrocytes. (**A**) Immunofluorescence analysis of hTERT-immortalised astrocytes transfected with CMYC/BRAF or the empty vector (EV) at 48 h using an antibody recognising the C-MYC tag (red), BRAF (green) and DAPI counterstaining (blue). (**B**) Immunofluorescence analysis of hTERT-immortalised astrocytes transfected with FLAG/HIPK2 or the EV at 48 h using an antibody recognising the FLAG tag (red) and DAPI counterstaining (blue). (**C**) Proliferation of hTERT-immortalised astrocytes was assessed at 48, 72 and 96 h following transfection with mock, BRAF, HIPK2 or both genes. No difference in the rate of cell growth was observed between the transfectant cells. Results represent the median of three separate experiments performed in triplicates. (**C**) Total cell extracts of hTERT-immortalised astrocytes transfected with the empty-vector or C-Myc-tagged BRAF. Cells were serum starved overnight before protein lysate extraction. (**D**) Left panel: hTERT-immortalised astrocytes were transiently transfected with CMYC/BRAF or the empty vector. Cells were serum starved overnight and total protein lysates extracted at 48 h posttransfection. Western blot analysis for C-Myc, BRAF, phopshoERK (pERK) and *β*-actin (loading control) was performed. Right panel: Empty-vector (EV) and C-Myc/BRAF transfectant hTERT-immortalised astrocytes were stimulated with 200 ng of epidermal growth factor (EGF) for 5 and 15 min. Total cell lysates extracted at baseline (0) and following activation (5, 15 min) with EGF were immunoblotted using antibodies against *β*-actin (loading control) and phosphorylated ERK (pERK), C-Myc and BRAF. Note the shift of BRAF immunoreactive band following EGF activation which indicates phosphorylation of the kinase and increase in its molecular weight. Importantly, increase in pERK levels relative to baseline following EGF stimulation was two fold higher in C-MYC/BRAF transfectant cells than in EV transfectants. Results represent the median of three separate experiments (*P*\<0.001).](6605179f4){#fig4}

###### 

Characteristics of the 53 sporadic juvenile pilocytic astrocytomas (JPA) included in the study

  **Patients**                                                    **Age (years)**   **Location**     **HIPK2 (qPCR)**   **BRAF (qPCR)**   **SNP array**   **Amplification of 7q34**   **pERK (IHC)**   **BRAFV600E**    
  --------------------------------------------------------------- ----------------- ---------------- ------------------ ----------------- --------------- --------------------------- ---------------- --------------- -----------
  *Cerebellar JPA (*n*=30)*                                                                                                                                                                                            
    1                                                             6                 Cerebellar       ND                 ND                7q34 amp        Y                           ND               ND               
    2                                                             6                 Cerebellar       ND                 ND                7q34 amp        Y                           ND               ND               
    3                                                             6                 Cerebellar       ND                 ND                7q34 amp        Y                           ND               ND               
    4                                                             6                 Cerebellar       ND                 ND                7q34 amp        Y                           ND               ND               
    5                                                             6                 Cerebellar       ND                 ND                7q34 amp        Y                           ND               ND               
    6                                                             6                 Cerebellar       ND                 ND                7q34 amp        Y                           ND               ND               
    7                                                             6                 Cerebellar       ND                 ND                7q34 amp        Y                           ND               ND               
    8                                                             6                 Cerebellar       ND                 ND                7q34 amp        Y                           ND               ND               
    9                                                             4                 Cerebellar       A                  A                 7q34 amp        Y                           Pos              WT               
   10                                                             4                 Cerebellar       A                  A                 7q34 amp        Y                           Pos              WT               
   11                                                             4                 Cerebellar       N                  N                 N               N                           Pos              WT               
   12                                                             4                 Cerebellar       A                  A                 7q34 amp        Y                           Pos              WT               
   13                                                             4                 Cerebellar       N                  N                 ND              N                           Pos              ND               
   14                                                             4                 Cerebellar       A                  A                 7q34 amp        Y                           Pos              WT               
   15                                                             4                 Cerebellar       ND                 ND                N               N                           Pos              ND               
   16                                                             4                 Cerebellar       A                  A                 7q34 amp        Y                           Pos              WT               
   17                                                             3                 Cerebellar       N                  N                 N               N                           Pos              WT               
   18                                                             6                 Cerebellar       N                  N                 N               N                           Pos              BRAFV600E        
   19                                                             11                Cerebellar       A                  A                 7q34 amp        Y                           Pos              WT               
   20                                                             11                Cerebellar       A                  A                 7q34 amp        Y                           Pos              WT               
   21                                                             6                 Cerebellar       A                  A                 ND              Y                           Pos              WT               
   22                                                             11                Cerebellar       A                  A                 ND              Y                           Pos              WT               
   23                                                             9                 Cerebellar       N                  N                 ND              N                           Pos              WT               
   24                                                             4                 Cerebellar       A                  A                 ND              Y                           Pos              WT               
   25                                                             8                 Cerebellar       A                  A                 ND              Y                           Pos              WT               
   26                                                             2                 Cerebellar       A                  A                 ND              Y                           Pos              WT               
   27                                                             9                 Cerebellar       A                  A                 ND              Y                           Pos              WT               
   28                                                             16                Cerebellar       A                  A                 ND              Y                           Pos              WT               
   29                                                             2                 Cerebellar       A                  A                 ND              Y                           Pos              WT               
   30                                                             14                Cerebellar       A                  A                 ND              Y                           Pos              WT              *N*=24/30
                                                                                                                                                                                                                        
  *Brainstem, hypothalamus and optic pathway (OP) JPA (*n*=16)*                                                                                                                                                        
   31                                                             18                Brainstem        N                  N                 ND              N                           Pos              ND               
   32                                                             6                 Brainstem        N                  N                 ND              N                           Pos              ND               
   33                                                             3                 Brainstem        N                  N                 ND              N                           Pos              ND               
   34                                                             1                 Brainstem        A                  A                 7q34 amp        Y                           Pos              WT               
   35                                                             9                 Brainstem        A                  A                 7q34 amp        Y                           Pos              WT               
   36                                                             4                 Brainstem        A                  A                 7q34 amp        Y                           Pos              WT               
   37                                                             6                 Brainstem        A                  N                 ND              Y-HIPK2                     Pos              WT               
   38                                                             6                 OP               A                  A                 ND              Y                           Pos              ND               
   39                                                             12                OP               A                  A                 ND              Y                           Pos              ND               
   40                                                             11                OP               A                  A                 ND              Y                           Pos              WT               
   41                                                             6                 OP               ND                 ND                N               N                           ND               ND               
   42                                                             6                 OP               ND                 ND                7q34 amp        Y                           ND               ND               
   43                                                             3                 OP               A                  A                 ND              Y                           Pos              WT               
   44                                                             7                 OP               A                  A                 7q34 amp        Y                           Pos              ND               
   45                                                             6                 OP               ND                 ND                N               N                           ND               ND               
   46                                                             6                 OP               ND                 ND                N               N                           ND               ND              *N*=10/16
                                                                                                                                                                                                                        
  *Hemispheric JPA (*n*=7)*                                                                                                                                                                                            
   47                                                             6                 Parietal         ND                 ND                N               N                           ND               ND               
   48                                                             10                Parietal         N                  N                 N               N                           Pos              WT               
   49                                                             13                Occipital lobe   N                  N                 N               N                           Pos              WT               
   50                                                             6                 Temporal         A                  N                 ND              Y-HIPK2                     Pos              WT               
   51                                                             4                 Occipital        N                  N                 ND              N                           Pos              WT               
   52                                                             6                 Temporal         ND                 ND                N               N                           ND               ND               
   53                                                             15                Ventricular      ND                 N                 N               N                           Pos              ND              *N*=1/7
                                                                                                                                                                                                                       *N*=35/53

N=negative; A=amplified; ND=not done; WT=wild type; Pos=positive; qPCR=quantitative real-time PCR; pERK=phospho-ERK; IHC=immunohistochemistry.

###### 

Characteristics of the other low-grade gliomas included in this study

  **Patients**                                  **Age (years)**   **Location**        **Pathology**         **HIP2K (qPCR)**   **BRAF (qPCR)**   **SNP array**   **Amplification of 7q34**   **pERK (IHC)**   **BRAF V600E**
  --------------------------------------------- ----------------- ------------------- --------------------- ------------------ ----------------- --------------- --------------------------- ---------------- ----------------
  *Optic pathway NF-1-associated JPA (*n*=4)*                                                                                                                                                                 
   54                                           7                 Optic pathway       JPA/NF1               ND                 ND                N               N                           ND               ND
   55                                           7                 Optic pathway       JPA/NF1               ND                 ND                N               N                           ND               ND
   56                                           7                 Optic pathway       JPA/NF1               ND                 ND                N               N                           ND               ND
   57                                           7                 Optic pathway       JPA/NF1               ND                 ND                N               N                           ND               ND
                                                                                                                                                                                                               
  *Other low grade gliomas (*n*=33)*                                                                                                                                                                          
   58                                           6                 Parietal lobe       Diffuse astrocytoma   ND                 ND                N               N                           ND               ND
   59                                           7                 Posterior fossa     Diffuse astrocytoma   ND                 ND                N               N                           ND               ND
   60                                           2                 Posterior fossa     Diffuse astrocytoma   N                  N                 ND              N                           Pos              ND
   61                                           14                Temporal lobe       Diffuse astrocytoma   N                  N                 ND              N                           Pos              ND
   62                                           10                Temporal lobe       Diffuse astrocytoma   N                  N                 ND              N                           Pos              ND
   63                                           0.25              Temporal lobe       Diffuse astrocytoma   A                  N                 ND              Y-HIP2K                     Pos              WT
   64                                           6                 Posterior fossa     Diffuse astrocytoma   ND                 ND                N               N                           ND               ND
   65                                           13                Posterior fossa     Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   66                                           6                 Temporal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   67                                           5                 Fourth ventricule   Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   68                                           2                 Parietal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   69                                           14                Posterior fossa     Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   70                                           12                Posterior fossa     Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   71                                           11                Temporal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   72                                           10                Temporal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   73                                           7                 Temporal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   74                                           9                 Posterior fossa     Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   75                                           12                Parietal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   76                                           15                Temporal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   77                                           2                 Posterior fossa     Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   78                                           9                 Parietal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   79                                           18                Temporal lobe       Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   80                                           5                 Brainstem           Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   81                                           3                 Brainstem           Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   82                                           2                 Hippocampus         Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   83                                           11                Hipothalamus        Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   84                                           14                Posterior fossa     Diffuse astrocytoma   N                  N                 ND              N                           ND               ND
   85                                           6                 Frontal lobe        Ganglioglioma         ND                 ND                N               N                           ND               ND
   86                                           6                 Brainstem           Ganglioglioma         ND                 ND                N               N                           ND               ND
   87                                           3                 Temporal lobe       Ganglioglioma         N                  N                 N               N                           Pos              WT
   88                                           16                Hippocampus         Ganglioglioma         N                  A                 N               N                           Pos              WT
   89                                           1                 Hippocampus         Ganglioglioma         N                  N                 N               N                           Pos              M
   90                                           18                Cauda equina        Ependymoma            N                  N                 N               N                           Pos              WT

JPA=juvenile pilocytic astrocytoma; M=V600E mutation; NF1=neurofibromatosis 1; SNP=single nucleotide polymorphism; qPCR=quantitative real-time PCR; pERK=phospho-ERK; IHC=immunohistochemistry; N=negative; A=amplified; ND=not done; WT=wild type; Pos=positive; M=mutated.

###### 

Clinical characteristics of samples from children with high-rade astrocytomas included in this study

  ------------------------ --------------------------
  Number of patients       25
                            
  *Gender*                 
   Male                    14
   Female                  11
                            
  Median age               12 years (10--18 months)
                            
  *WHO classification*     
   Astrocytomas grade IV   18
   Astrocytoma grade III   7
                            
  *Tumor site*             
   Supratentorial          18
   Infratentorial          6
   Mixed                   1
  ------------------------ --------------------------

###### 

Genomic alterations in 10 JPA with no 7q34 duplications and 5 grade II astrocytomas

  **Minimal common region**      **Cerebellar**   **Brainstem and optic**   **Hemispheric**   **Grade II**                   
  ------------------------------ ---------------- ------------------------- ----------------- -------------- --- --- --- --- --------------------------------------------
  *Homozygous deletions*                                                                                                     
   1p36.13                       17085956         17155012                  11                69056          4   1   1       LOC100129182, TRNAN2, CROCC
   1q21.2                        147282617        147427061                 15                144444         2               FJL12528, ECM1, FJ13544, TSRC1, MCL1, ENSA
   2p16.2                        52995459         53070421                  10                                   1           LOC402072
   2q31.2                        180123158        180129913                 11                6755           1       1       ZNF385B
   2q13                          110201336        111021091                 48                819755         1   1           Mall, NPHP1, FLJ, RGPD6, RGPD7
   3p21.3                        37954886         37961253                  15                6367           1   2           CTDSPL
   3p21.1                        53003023         53021256                  13                18233          1   1           SFMBT1
   3q28                          191217916        191221750                 11                3835           3   2           CCD50
   4q13.2                        69064675         69163188                  36                98513          1   1   1       UGT2B29P, UGT2B17, LOC100132651
   4q34.1                        173218118        173236491                 105               18373          2               GALNT17
   5p15.33                       812485           873185                    17                60700          1   2           ZDHHC11B, ZDHHC11
   5q15                          97053242         97121798                                    8              1               LOC391813
   5q35.3                        180307066        180363775                 11                56709          1       1       BTNL8, LOC, BTNL3
   7q11.22                       67054161         67482237                  54                                   1           LOC441249
   8p23.1                        12257261         12388979                  16                131719             2           ZNF705C, FAM, FAM,
   9p11.2                        44683090         44770712                  20                87623          2   1   1       LOC
   11q11                         55124465         55209499                  49                85035          1   1           OR4C11, OR4P4, OR4S2, OR
   11q11                         55447435         55484857                  8                                    1           OR5I1, OR10AF1P, OR10AK1P
   12p13.31                      9526879          9607393                   15                80515          3   2           Ovostatin
   17p11.2                       18292126         18398047                  9                 105922         1   1           NOS2B, FAM, LOC
   19q13.2                       46047894         46075668                  22                27774          2               CYP2A6, CYP2A7
   19q13.41                      56230373         56263967                                    8                  1           KLK13
   20q13.2                       52080333         52088118                  23                7786           2               BCAS1
   21q21.3                       26136162         26176988                                    8              1               APP
                                                                                                                              
  *Chromosomal amplifications*                                                                                               
   1p31.1                        74447282         74631475                  16                               1               TNNI3K
   1q43                          234665731        234752676                 84                86946          2               EDARADD, ENO1P, LGALS8
   2p11.2                        86152633         86343699                  20                                   1           POLR1A, FLJ20758, IMMT, MRPL35
   4p12                          47678100         47893952                  50                139606         1               NPAL1, TXK, TEC
   4q12                          54076102         55611307                  88                               1               FIP1L1, LNX1, CHIC2, GSH-2, PDGFRa, KIT
   5q35.3                        178337857        178528476                 30                               1               GRM6, ZNF354C, LOC645944, ADAMTS2
   5q11.2                        53507913         53670668                  128               162756         1               ARL15
   6q27                          168091860        168319676                 209               227817         2   1           MLLT4, LOC100128124, KIF25, FRMD1
   8p12-8p11.23                  38405382         38873687                  41                                           2   FGFR1, FLJ43582, TACC1
   8p23.1                        8102456          8182850                   26                80395              1           FLJ10661, LOC1001
   10q11.22                      47007374         47167032                  82                74264          2   1           LOC340844, LOC728684, ANTXRL
   10q26.3                       135116379        135202003                 14                                           2   Sprn, OR6LP2, LOC399832, OR7M1P
   12p13.31                      7895025          8014573                   56                119549         1               SLC2A14, LOC, NANOGP1, SLC2A3, NECAP1
   12p11.21                      31157554         31300846                  55                143293         3   2   2   2   LOC100132881, OVOS2, LOC441632
   12q14.2                       62294703         62415375                  7                                1               FLJ32949, LOC390338
   14q11.2                       19283777         19493705                  28                209929             1           All olfactory receptors
   14q24.1-14q24.2               69202898         69470896                  32                                   1           KIAA0247, SFRS5, SLC10A1, RPL7AP6, SMOC1
   15q11.2                       19359417         19523964                  26                164548                 1       LOC, OR11J2P, OR11J5P
   15q26.3                       99310512         99791921                  204               481410         1               LRRK1, CHSY1, SELS, SNRPA1, PCSK6
   17q25.3                       74877129         74905197                  48                28069              1           LOC, HRNBP3
   19q13.31                      47948855         48150403                  26                201549         2               Pregnancy specific beta-1-glycoproteins
   19q13.42                      59971240         60054671                  14                83432          1   3   2       KIR2DL1-4, KIR3DP1, KIR3DL1, KIR2DS1-4
   20p13                         1593502          1663448                   41                69947          1               LOC
   21q22.2                       39823301         39835430                  15                12130          1               LOC
   22q11.23                      23991725         24240667                  94                248943         1               IGLL3, LRP5L, LOC, CRYBB2P1
   22q11.21                      17257787         17388108                  73                130322         1               LOC, DGCR6, PRODH, DGCR5
